Kenmerk
Stroke
Sudden impairment of blood flow to a part of the brain due to occlusion or rupture of an artery to the brain.
Samenvatting
- Ook bekend als
- Cerebral vascular events, Cerebrovascular accident
ReferentiegenoomGRCh38hg38
Posities op gen- en variantpagina's volgen deze keuze, in deze browser.
Read the genes linked to Stroke, and the rest of your genome, with one test.
Vanaf $ 449Gratis verzending · Resultaten binnen 6–8 weken
Mijn Genome Test bestellen145 genen gekoppeld aan Stroke
Veranderingen in deze genen veroorzaken zeldzame aandoeningen waarbij Stroke voorkomt. De meeste mensen met dit kenmerk hebben geen van die aandoeningen, en een gen op deze lijst zegt niets over het eigen genoom van iemand.
| Gen | Hoe vaak het voorkomt | Aandoeningen |
|---|---|---|
| ADA2adenosine deaminase 2 | Altijd | In 2 aandoeningen |
| ALPK3alpha kinase 3 | Altijd | In 1 aandoening |
| APPamyloid beta precursor protein | Altijd | In 5 aandoeningen |
| CST3cystatin C | Altijd | In 3 aandoeningen |
| F8coagulation factor VIII | Altijd | In 1 aandoening |
| GGCXgamma-glutamyl carboxylase | Altijd | In 1 aandoening |
| GUCY1A1guanylate cyclase 1 soluble subunit alpha 1 | Altijd | In 1 aandoening |
| SPOUT1SPOUT domain containing methyltransferase 1 | Altijd | In 1 aandoening |
| TPP2tripeptidyl peptidase 2 | Heel vaak (80–99%) | In 1 aandoening |
| BAZ1Bbromodomain adjacent to zinc finger domain 1B | Vaak (30–79%) | In 1 aandoening |
| BUD23BUD23 rRNA methyltransferase and ribosome maturation factor | Vaak (30–79%) | In 1 aandoening |
| CLIP2CAP-Gly domain containing linker protein 2 | Vaak (30–79%) | In 1 aandoening |
| DNAJC30DnaJ heat shock protein family (Hsp40) member C30 | Vaak (30–79%) | In 1 aandoening |
| EFEMP2EGF-like fibulin extracellular matrix protein 2 | Vaak (30–79%) | In 2 aandoeningen |
| EIF4Heukaryotic translation initiation factor 4H | Vaak (30–79%) | In 1 aandoening |
| ELNelastin | Vaak (30–79%) | In 3 aandoeningen |
| FKBP6FKBP prolyl isomerase family member 6 (inactive) | Vaak (30–79%) | In 1 aandoening |
| GNAQG protein subunit alpha q | Vaak (30–79%) | In 1 aandoening |
| GTF2Igeneral transcription factor IIi | Vaak (30–79%) | In 1 aandoening |
| GTF2IRD1GTF2I repeat domain containing 1 | Vaak (30–79%) | In 1 aandoening |
| GTF2IRD2GTF2I repeat domain containing 2 | Vaak (30–79%) | In 1 aandoening |
| HTRA1HtrA serine peptidase 1 | Vaak (30–79%) | In 3 aandoeningen |
| LIMK1LIM domain kinase 1 | Vaak (30–79%) | In 1 aandoening |
| METTL27methyltransferase like 27 | Vaak (30–79%) | In 1 aandoening |
| NCF1neutrophil cytosolic factor 1 | Vaak (30–79%) | In 1 aandoening |
| NIT1nitrilase 1 | Vaak (30–79%) | In 1 aandoening |
| NOTCH3notch receptor 3 | Vaak (30–79%) | In 3 aandoeningen |
| PIK3C2Aphosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha | Vaak (30–79%) | In 1 aandoening |
| PLIN1perilipin 1 | Vaak (30–79%) | In 1 aandoening |
| RFC2replication factor C subunit 2 | Vaak (30–79%) | In 1 aandoening |
| SCN5Asodium voltage-gated channel alpha subunit 5 | Vaak (30–79%) | In 2 aandoeningen |
| SMARCAL1SNF2 related chromatin remodeling annealing helicase 1 | Vaak (30–79%) | In 2 aandoeningen |
| SOX17SRY-box transcription factor 17 | Vaak (30–79%) | In 1 aandoening |
| STX1Asyntaxin 1A | Vaak (30–79%) | In 1 aandoening |
| TBL2transducin beta like 2 | Vaak (30–79%) | In 1 aandoening |
| TMEM270transmembrane protein 270 | Vaak (30–79%) | In 1 aandoening |
| VPS37DVPS37D subunit of ESCRT-I | Vaak (30–79%) | In 1 aandoening |
| ABCC6ATP binding cassette subfamily C member 6 | Soms (5–29%) | In 3 aandoeningen |
| ACTA2actin alpha 2, smooth muscle | Soms (5–29%) | In 1 aandoening |
| ADAMTS13ADAM metallopeptidase with thrombospondin type 1 motif 13 | Soms (5–29%) | In 1 aandoening |
Toon nog 105 genen
| Gen | Hoe vaak het voorkomt | Aandoeningen |
|---|---|---|
| ASS1argininosuccinate synthase 1 | Soms (5–29%) | In 1 aandoening |
| ATRXATRX chromatin remodeler | Soms (5–29%) | In 1 aandoening |
| B3GALT6beta-1,3-galactosyltransferase 6 | Soms (5–29%) | In 1 aandoening |
| BRAFB-Raf proto-oncogene, serine/threonine kinase | Soms (5–29%) | In 1 aandoening |
| CCND1cyclin D1 | Soms (5–29%) | In 1 aandoening |
| CDH23cadherin related 23 | Soms (5–29%) | In 1 aandoening |
| CPS1carbamoyl-phosphate synthase 1 | Soms (5–29%) | In 1 aandoening |
| CYP11B1cytochrome P450 family 11 subfamily B member 1 | Soms (5–29%) | In 1 aandoening |
| CYP11B2cytochrome P450 family 11 subfamily B member 2 | Soms (5–29%) | In 1 aandoening |
| DYRK1Bdual specificity tyrosine phosphorylation regulated kinase 1B | Soms (5–29%) | In 1 aandoening |
| EMILIN1elastin microfibril interfacer 1 | Soms (5–29%) | In 1 aandoening |
| ENPP1ectonucleotide pyrophosphatase/phosphodiesterase 1 | Soms (5–29%) | In 2 aandoeningen |
| FBN1fibrillin 1 | Soms (5–29%) | In 1 aandoening |
| FHOD3formin homology 2 domain containing 3 | Soms (5–29%) | In 1 aandoening |
| FLNAfilamin A | Soms (5–29%) | In 1 aandoening |
| FLNCfilamin C | Soms (5–29%) | In 2 aandoeningen |
| FOXE3forkhead box E3 | Soms (5–29%) | In 1 aandoening |
| GLAgalactosidase alpha | Soms (5–29%) | In 1 aandoening |
| HEY2hes related family bHLH transcription factor with YRPW motif 2 | Soms (5–29%) | In 1 aandoening |
| HLA-Bmajor histocompatibility complex, class I, B | Soms (5–29%) | In 1 aandoening |
| HSD11B2hydroxysteroid 11-beta dehydrogenase 2 | Soms (5–29%) | In 1 aandoening |
| IL12Binterleukin 12B | Soms (5–29%) | In 1 aandoening |
| JAK2Janus kinase 2 | Soms (5–29%) | In 1 aandoening |
| LMNAlamin A/C | Soms (5–29%) | In 1 aandoening |
| LOXlysyl oxidase | Soms (5–29%) | In 1 aandoening |
| MAT2Amethionine adenosyltransferase 2A | Soms (5–29%) | In 1 aandoening |
| MECP2methyl-CpG binding protein 2 | Soms (5–29%) | In 1 aandoening |
| MFAP5microfibril associated protein 5 | Soms (5–29%) | In 1 aandoening |
| MLXMAX dimerization protein MLX | Soms (5–29%) | In 1 aandoening |
| MMUTmethylmalonyl-CoA mutase | Soms (5–29%) | In 1 aandoening |
| MYBPC3myosin binding protein C3 | Soms (5–29%) | In 1 aandoening |
| MYD88MYD88 innate immune signal transduction adaptor | Soms (5–29%) | In 1 aandoening |
| MYH11myosin heavy chain 11 | Soms (5–29%) | In 3 aandoeningen |
| MYLKmyosin light chain kinase | Soms (5–29%) | In 1 aandoening |
| NF1neurofibromin 1 | Soms (5–29%) | In 1 aandoening |
| NR3C1nuclear receptor subfamily 3 group C member 1 | Soms (5–29%) | In 2 aandoeningen |
| OTCornithine transcarbamylase | Soms (5–29%) | In 1 aandoening |
| PCNTpericentrin | Soms (5–29%) | In 1 aandoening |
| PDE11Aphosphodiesterase 11A | Soms (5–29%) | In 1 aandoening |
| PIGAphosphatidylinositol glycan anchor biosynthesis class A | Soms (5–29%) | In 1 aandoening |
| PRKAR1Aprotein kinase cAMP-dependent type I regulatory subunit alpha | Soms (5–29%) | In 1 aandoening |
| PRKG1protein kinase cGMP-dependent 1 | Soms (5–29%) | In 1 aandoening |
| SLC19A2solute carrier family 19 member 2 | Soms (5–29%) | In 2 aandoeningen |
| SMAD2SMAD family member 2 | Soms (5–29%) | In 1 aandoening |
| SMAD3SMAD family member 3 | Soms (5–29%) | In 1 aandoening |
| SMAD4SMAD family member 4 | Soms (5–29%) | In 2 aandoeningen |
| SNAP29synaptosome associated protein 29 | Soms (5–29%) | In 1 aandoening |
| SNORD118small nucleolar RNA, C/D box 118 | Soms (5–29%) | In 1 aandoening |
| TANGO2transport and golgi organization 2 homolog | Soms (5–29%) | In 1 aandoening |
| TGFB2transforming growth factor beta 2 | Soms (5–29%) | In 1 aandoening |
| TGFB3transforming growth factor beta 3 | Soms (5–29%) | In 1 aandoening |
| TGFBR1transforming growth factor beta receptor 1 | Soms (5–29%) | In 1 aandoening |
| TGFBR2transforming growth factor beta receptor 2 | Soms (5–29%) | In 1 aandoening |
| THSD4thrombospondin type 1 domain containing 4 | Soms (5–29%) | In 1 aandoening |
| TNXBtenascin XB | Soms (5–29%) | In 1 aandoening |
| TP53tumor protein p53 | Soms (5–29%) | In 1 aandoening |
| TRPV6transient receptor potential cation channel subfamily V member 6 | Soms (5–29%) | In 1 aandoening |
| TTRtransthyretin | Soms (5–29%) | In 1 aandoening |
| USP48ubiquitin specific peptidase 48 | Soms (5–29%) | In 1 aandoening |
| USP8ubiquitin specific peptidase 8 | Soms (5–29%) | In 1 aandoening |
| VHLvon Hippel-Lindau tumor suppressor | Soms (5–29%) | In 2 aandoeningen |
| ZAP70zeta chain of T cell receptor associated protein kinase 70 | Soms (5–29%) | In 1 aandoening |
| ZMPSTE24zinc metallopeptidase STE24 | Soms (5–29%) | In 1 aandoening |
| ACTC1actin alpha cardiac muscle 1 | Zelden (1–4%) | In 1 aandoening |
| AGXTalanine--glyoxylate aminotransferase | Zelden (1–4%) | In 1 aandoening |
| CITED2Cbp/p300 interacting transactivator with ED-rich tail 2 | Zelden (1–4%) | In 2 aandoeningen |
| ERCC6ERCC excision repair 6, chromatin remodeling factor | Zelden (1–4%) | In 1 aandoening |
| ERCC8ERCC excision repair 8, CSA ubiquitin ligase complex subunit | Zelden (1–4%) | In 1 aandoening |
| GATA4GATA binding protein 4 | Zelden (1–4%) | In 1 aandoening |
| GATA6GATA binding protein 6 | Zelden (1–4%) | In 1 aandoening |
| KIF20Akinesin family member 20A | Zelden (1–4%) | In 1 aandoening |
| MLXIPLMLX interacting protein like | Zelden (1–4%) | In 1 aandoening |
| MMACHCmetabolism of cobalamin associated C | Zelden (1–4%) | In 1 aandoening |
| MTHFRmethylenetetrahydrofolate reductase | Zelden (1–4%) | In 2 aandoeningen |
| MYH6myosin heavy chain 6 | Zelden (1–4%) | In 1 aandoening |
| MYH7myosin heavy chain 7 | Zelden (1–4%) | In 1 aandoening |
| MYPNmyopalladin | Zelden (1–4%) | In 1 aandoening |
| NAGSN-acetylglutamate synthase | Zelden (1–4%) | In 1 aandoening |
| NKX2-5NK2 homeobox 5 | Zelden (1–4%) | In 1 aandoening |
| PNPpurine nucleoside phosphorylase | Zelden (1–4%) | In 1 aandoening |
| TBX20T-box transcription factor 20 | Zelden (1–4%) | In 1 aandoening |
| TLL1tolloid like 1 | Zelden (1–4%) | In 1 aandoening |
| TNNI3troponin I3, cardiac type | Zelden (1–4%) | In 1 aandoening |
| TNNT2troponin T2, cardiac type | Zelden (1–4%) | In 1 aandoening |
| XYLT1xylosyltransferase 1 | Zelden (1–4%) | In 1 aandoening |
| XYLT2xylosyltransferase 2 | Zelden (1–4%) | In 1 aandoening |
| ACAD9acyl-CoA dehydrogenase family member 9 | Niet vastgelegd | In 1 aandoening |
| ALOX5AParachidonate 5-lipoxygenase activating protein | Niet vastgelegd | In 1 aandoening |
| ANO1anoctamin 1 | Niet vastgelegd | In 1 aandoening |
| CBScystathionine beta-synthase | Niet vastgelegd | In 1 aandoening |
| CCM2CCM2 scaffold protein | Niet vastgelegd | In 1 aandoening |
| CHMP2Bcharged multivesicular body protein 2B | Niet vastgelegd | In 1 aandoening |
| F2coagulation factor II, thrombin | Niet vastgelegd | In 1 aandoening |
| F5coagulation factor V | Niet vastgelegd | In 1 aandoening |
| GRNgranulin precursor | Niet vastgelegd | In 1 aandoening |
| GYS1glycogen synthase 1 | Niet vastgelegd | In 1 aandoening |
| HBBhemoglobin subunit beta | Niet vastgelegd | In 1 aandoening |
| JAG1jagged canonical Notch ligand 1 | Niet vastgelegd | In 1 aandoening |
| MAPTmicrotubule associated protein tau | Niet vastgelegd | In 1 aandoening |
| NPPAnatriuretic peptide A | Niet vastgelegd | In 1 aandoening |
| PSEN1presenilin 1 | Niet vastgelegd | In 1 aandoening |
| TMEM106Btransmembrane protein 106B | Niet vastgelegd | In 1 aandoening |
| TREM2triggering receptor expressed on myeloid cells 2 | Niet vastgelegd | In 1 aandoening |
| TREX1three prime repair exonuclease 1 | Niet vastgelegd | In 1 aandoening |
| VCPvalosin containing protein | Niet vastgelegd | In 1 aandoening |
Hoe vaak dit voorkomt bij mensen met een van de aandoeningen van het gen, de hoogste frequentie binnen die aandoeningen, zoals de Human Phenotype Ontology dit vastlegt. Deze pagina's beschrijven kenmerken en het onderzoek erachter; het zijn geen diagnose, en over symptomen kunt u het best een arts of genetisch adviseur raadplegen.
Smallere kenmerken
Bredere kenmerken
Waar dit vandaan komt
- De Human Phenotype Ontology, release 2026-09-01: het kenmerk, de namen, de definitie en de genen die ermee verbonden zijn. Meer informatie vindt u op hpo.jax.org.
- Gegevensrelease 2026.10.16-c6eea6bf.
Eén test. Een leven lang antwoorden.
Vanaf $ 449Gratis verzending · Resultaten binnen 6–8 weken